184 related articles for article (PubMed ID: 19034238)
1. Efficacy of triple therapy with thymalfasin, peginterferon alpha-2a, and ribavirin for the treatment of hispanic chronic HCV nonresponders.
Poo JL; Sánchez Avila F; Kershenobich D; García Samper X; Torress-Ibarra R; Góngora J; Cano C; Parada M; Uribe M
Ann Hepatol; 2008; 7(4):369-75. PubMed ID: 19034238
[TBL] [Abstract][Full Text] [Related]
2. Peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a monotherapy in early virological responders and peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a, ribavirin and amantadine triple therapy in early virological nonresponders: the SMIEC II trial in naïve patients with chronic hepatitis C.
Angelico M; Koehler-Horst B; Piccolo P; Angelico F; Gentile S; Francioso S; Tarquini P; Vecchia RD; Ponti L; Pilleri G; Barlattani A; Grieco A; Soccorsi F; Guarascio P; Demelia L; Sorbello O; Rossi Z; Forlini G; Zaru S; Bandiera F;
Eur J Gastroenterol Hepatol; 2008 Jul; 20(7):680-7. PubMed ID: 18679072
[TBL] [Abstract][Full Text] [Related]
3. Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection.
Ascione A; De Luca M; Tartaglione MT; Lampasi F; Di Costanzo GG; Lanza AG; Picciotto FP; Marino-Marsilia G; Fontanella L; Leandro G
Gastroenterology; 2010 Jan; 138(1):116-22. PubMed ID: 19852964
[TBL] [Abstract][Full Text] [Related]
4. Triple combination of thymalfasin, peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior interferon and ribavirin treatment: 24-week interim results of a pilot study.
Poo JL; Sánchez-Avila F; Kershenobich D; García-Samper X; Gongora J; Uribe M
J Gastroenterol Hepatol; 2004 Dec; 19(12):S79-81. PubMed ID: 15641210
[TBL] [Abstract][Full Text] [Related]
5. Thymalfasin for the treatment of chronic hepatitis C infection.
Rustgi VK
Ann N Y Acad Sci; 2007 Sep; 1112():357-67. PubMed ID: 17600289
[TBL] [Abstract][Full Text] [Related]
6. A randomized controlled trial of pegylated interferon alpha-2a (40 KD) or interferon alpha-2a plus ribavirin and amantadine vs interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C.
Mangia A; Ricci GL; Persico M; Minerva N; Carretta V; Bacca D; Cela M; Piattelli M; Annese M; Maio G; Conte D; Guadagnino V; Pazienza V; Festi D; Spirito F; Andriulli A
J Viral Hepat; 2005 May; 12(3):292-9. PubMed ID: 15850470
[TBL] [Abstract][Full Text] [Related]
7. Improved virologic response in chronic hepatitis C genotype 4 treated with nitazoxanide, peginterferon, and ribavirin.
Rossignol JF; Elfert A; El-Gohary Y; Keeffe EB
Gastroenterology; 2009 Mar; 136(3):856-62. PubMed ID: 19135998
[TBL] [Abstract][Full Text] [Related]
8. Peginterferon alfa-2a (40KD) (PEGASYS) plus ribavirin (COPEGUS) in retreatment of chronic hepatitis C patients, nonresponders and relapsers to previous conventional interferon plus ribavirin therapy.
Parise E; Cheinquer H; Crespo D; Meirelles A; Martinelli A; Sette H; Gallizi J; Silva R; Lacet C; Correa E; Cotrim H; Fonseca J; Paraná R; Spinelli V; Amorim W; Tatsch F; Pessoa M;
Braz J Infect Dis; 2006 Feb; 10(1):11-6. PubMed ID: 16767309
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of peg-IFN alfa-2a with ribavirin for the treatment of HCV/HIV coinfected patients who failed previous IFN based therapy.
Rodríguez-Torres M; Rodríguez-Orengo JF; Ríos-Bedoya CF; Fernández-Carbia A; González-Lassalle E; Salgado-Mercado R; Marxuach-Cuétara AM
J Clin Virol; 2007 Jan; 38(1):32-8. PubMed ID: 17064957
[TBL] [Abstract][Full Text] [Related]
10. Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients.
Lawitz E; Rodriguez-Torres M; Muir AJ; Kieffer TL; McNair L; Khunvichai A; McHutchison JG
J Hepatol; 2008 Aug; 49(2):163-9. PubMed ID: 18486984
[TBL] [Abstract][Full Text] [Related]
11. Triple combination of thymalfasin, peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior interferon and ribavirin treatment: 24-week interim results of a pilot study.
Poo JL; Sánchez-Avila F; Kershenobich D; García-Samper X; Gongora J; Uribe M
J Gastroenterol Hepatol; 2004 Dec; 19 Suppl 6():S79-81. PubMed ID: 15546256
[TBL] [Abstract][Full Text] [Related]
12. Pioglitazone improves virological response to peginterferon alpha-2b/ribavirin combination therapy in hepatitis C genotype 4 patients with insulin resistance.
Khattab M; Emad M; Abdelaleem A; Eslam M; Atef R; Shaker Y; Hamdy L
Liver Int; 2010 Mar; 30(3):447-54. PubMed ID: 19919569
[TBL] [Abstract][Full Text] [Related]
13. Thymosin alpha-1 with peginterferon alfa-2a/ribavirin for chronic hepatitis C not responsive to IFN/ribavirin: an adjuvant role?
Ciancio A; Andreone P; Kaiser S; Mangia A; Milella M; Solà R; Pol S; Tsianos E; De Rosa A; Camerini R; McBeath R; Rizzetto M
J Viral Hepat; 2012 Jan; 19 Suppl 1():52-9. PubMed ID: 22233415
[TBL] [Abstract][Full Text] [Related]
14. Chronic hepatitis C genotype 1 patients with insulin resistance treated with pioglitazone and peginterferon alpha-2a plus ribavirin.
Harrison SA; Hamzeh FM; Han J; Pandya PK; Sheikh MY; Vierling JM
Hepatology; 2012 Aug; 56(2):464-73. PubMed ID: 22334369
[TBL] [Abstract][Full Text] [Related]
15. Interferon-gamma with peginterferon alpha-2a and ribavirin in nonresponder patients with chronic hepatitis C (ANRS HC16 GAMMATRI).
Couzigou P; Pérusat S; Bourlière M; Trimoulet P; Poynard T; Leroy V; Marcellin P; Foucher J; Bronowicki JP; Chêne G;
J Gastroenterol Hepatol; 2013 Feb; 28(2):329-34. PubMed ID: 23190183
[TBL] [Abstract][Full Text] [Related]
16. Response to pegylated interferon alfa-2a and ribavirin in chronic hepatitis C genotype 4.
El Makhzangy H; Esmat G; Said M; Elraziky M; Shouman S; Refai R; Rekacewicz C; Gad RR; Vignier N; Abdel-Hamid M; Zalata K; Bedossa P; Pol S; Fontanet A; Mohamed MK
J Med Virol; 2009 Sep; 81(9):1576-83. PubMed ID: 19626613
[TBL] [Abstract][Full Text] [Related]
17. A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C.
Yu ML; Dai CY; Huang JF; Hou NJ; Lee LP; Hsieh MY; Chiu CF; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Chuang WL
Gut; 2007 Apr; 56(4):553-9. PubMed ID: 16956917
[TBL] [Abstract][Full Text] [Related]
18. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in children and adolescents.
Sokal EM; Bourgois A; Stéphenne X; Silveira T; Porta G; Gardovska D; Fischler B; Kelly D
J Hepatol; 2010 Jun; 52(6):827-31. PubMed ID: 20400194
[TBL] [Abstract][Full Text] [Related]
19. A double-blind, randomized, placebo-controlled study to assess the safety, antiviral activity and pharmacokinetics of GSK2336805 when given as monotherapy and in combination with peginterferon alfa-2a and ribavirin in hepatitis C virus genotype 1-infected treatment-naive subjects.
Gardner S; Cutrell A; Elko-Simms C; Adkison K; Hamatake R; Walker J; Rodriguez-Torres M; Hong Z
Liver Int; 2014 Jul; 34(6):e89-95. PubMed ID: 24107072
[TBL] [Abstract][Full Text] [Related]
20. Comparison of low-dose pegylated interferon versus standard high-dose pegylated interferon in combination with ribavirin in patients with chronic hepatitis C with genotype 3: an Indian experience.
Sood A; Midha V; Hissar S; Kumar M; Suneetha PV; Bansal M; Sood N; Sakhuja P; Sarin SK
J Gastroenterol Hepatol; 2008 Feb; 23(2):203-7. PubMed ID: 17645472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
